Spark Therapeutics, Inc.
We are investigating Spark Therapeutics, Inc. (NasdaqGS: ONCE) relating to the sale of the Company to Roche Holdings, Inc. Under the terms of the agreement, Spark Therapeutics shareholders are only anticipated to receive $114.50 in cash for each share of Spark Therapeutics they own.